N-methyl-d-aspartate receptor antibody-related pathologies and pre-existent mental state disorders

[1]  Meredith J. McHugh,et al.  Broad clinical high‐risk mental state (CHARMS): Methodology of a cohort study validating criteria for pluripotent risk , 2019, Early intervention in psychiatry.

[2]  S. Sartori,et al.  N-methyl-D-aspartate receptor encephalitis: laboratory diagnostics and comparative clinical features in adults and children , 2018, Expert review of molecular diagnostics.

[3]  J. Suvisaari,et al.  Anti-neuronal anti-bodies in patients with early psychosis , 2017, Schizophrenia Research.

[4]  M. Leboyer,et al.  Dynamic disorganization of synaptic NMDA receptors triggered by autoantibodies from psychotic patients , 2017, Nature Communications.

[5]  M. Kamoun,et al.  Improving the antibody-based evaluation of autoimmune encephalitis , 2017, Neurology: Neuroimmunology & Neuroinflammation.

[6]  A. Vincent,et al.  Pitfalls in the detection of N-methyl-d-aspartate-receptor (NMDA-R) antibodies. , 2017, Clinical biochemistry.

[7]  A. Venkatesan,et al.  A clinical approach to diagnosis of autoimmune encephalitis , 2016, The Lancet Neurology.

[8]  Jim van Os,et al.  Late onset autism and anti-NMDA-receptor encephalitis , 2011, The Lancet.

[9]  R. Balice-Gordon,et al.  Clinical experience and laboratory investigations in patients with anti-NMDAR encephalitis , 2011, The Lancet Neurology.

[10]  Tyrone D. Cannon,et al.  Prediction of psychosis in youth at high clinical risk: a multisite longitudinal study in North America. , 2008, Archives of general psychiatry.

[11]  Godfrey D Pearlson,et al.  Prodromal assessment with the structured interview for prodromal syndromes and the scale of prodromal symptoms: predictive validity, interrater reliability, and training to reliability. , 2003, Schizophrenia bulletin.